1. Home
  2. GANX vs ALAR Comparison

GANX vs ALAR Comparison

Compare GANX & ALAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • ALAR
  • Stock Information
  • Founded
  • GANX 2017
  • ALAR 2013
  • Country
  • GANX United States
  • ALAR Israel
  • Employees
  • GANX N/A
  • ALAR N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • ALAR Computer Software: Prepackaged Software
  • Sector
  • GANX Health Care
  • ALAR Technology
  • Exchange
  • GANX Nasdaq
  • ALAR Nasdaq
  • Market Cap
  • GANX 45.8M
  • ALAR 41.3M
  • IPO Year
  • GANX 2021
  • ALAR 2018
  • Fundamental
  • Price
  • GANX $1.94
  • ALAR $6.82
  • Analyst Decision
  • GANX Strong Buy
  • ALAR Strong Buy
  • Analyst Count
  • GANX 5
  • ALAR 1
  • Target Price
  • GANX $8.20
  • ALAR $11.00
  • AVG Volume (30 Days)
  • GANX 310.3K
  • ALAR 86.4K
  • Earning Date
  • GANX 05-20-2025
  • ALAR 05-29-2025
  • Dividend Yield
  • GANX N/A
  • ALAR N/A
  • EPS Growth
  • GANX N/A
  • ALAR N/A
  • EPS
  • GANX N/A
  • ALAR 0.08
  • Revenue
  • GANX N/A
  • ALAR $31,824,000.00
  • Revenue This Year
  • GANX N/A
  • ALAR N/A
  • Revenue Next Year
  • GANX N/A
  • ALAR $12.28
  • P/E Ratio
  • GANX N/A
  • ALAR $8.53
  • Revenue Growth
  • GANX N/A
  • ALAR 20.00
  • 52 Week Low
  • GANX $0.89
  • ALAR $5.45
  • 52 Week High
  • GANX $3.19
  • ALAR $46.69
  • Technical
  • Relative Strength Index (RSI)
  • GANX 50.18
  • ALAR 48.34
  • Support Level
  • GANX $1.85
  • ALAR $6.31
  • Resistance Level
  • GANX $2.07
  • ALAR $7.15
  • Average True Range (ATR)
  • GANX 0.15
  • ALAR 0.44
  • MACD
  • GANX 0.02
  • ALAR -0.02
  • Stochastic Oscillator
  • GANX 40.00
  • ALAR 36.69

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.

Share on Social Networks: